BridgeBio Pharma (BBIO) Revenue (2019 - 2026)
BridgeBio Pharma (BBIO) posted Revenue of $194.5 million for Q1 2026, up 26.16% sequentially from $154.2 million in Q4 2025, and up 66.78% YoY from $116.6 million in Q1 2025.
BridgeBio Pharma (BBIO) Revenue (2019 - 2026) Analysis & Trends
BridgeBio Pharma has reported Revenue for 8 years, with the latest figure at $194.5 million in Q1 2026.
- Quarterly Revenue rose 66.78% year-over-year to $194.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $580.0 million (up 355.17% YoY) and the FY2025 annual result came in at $502.1 million, up 126.26% from the prior year.
- Revenue improved to $194.5 million in Q1 2026 per BBIO's latest filing, from $154.2 million in the prior quarter.
- Over five years, Revenue peaked at $211.1 million in Q1 2024 and troughed at $338000.0 in Q3 2022.
- A 5-year average of $59.1 million and a median of $4.1 million in 2023 frame the typical range for Revenue.
- The sharpest annual moves came in 2023 and 2024: Revenue plunged 97.77% in 2023, then jumped 11461.88% in 2024.
- Over 5 years, Revenue stood at $1.9 million in 2022, then retreated by 6.68% to $1.7 million in 2023, then soared by 237.08% to $5.9 million in 2024, then soared by 2521.18% to $154.2 million in 2025, then rose by 26.16% to $194.5 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $194.5 million, $154.2 million, and $120.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | BridgeBio Pharma | 15.60 Bn | 14.89 Bn | 228.63 Mn | 243.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 243.68 Mn |
| Mar 31, 2026 | 194.52 Mn |
| Dec 31, 2025 | 154.18 Mn |
| Sep 30, 2025 | 120.70 Mn |
| Jun 30, 2025 | 110.57 Mn |
| Mar 31, 2025 | 116.63 Mn |
| Dec 31, 2024 | 5.88 Mn |
| Sep 30, 2024 | 2.73 Mn |
| Jun 30, 2024 | 2.17 Mn |
| Mar 31, 2024 | 211.12 Mn |
| Dec 31, 2023 | 1.75 Mn |
| Sep 30, 2023 | 4.09 Mn |
| Jun 30, 2023 | 1.64 Mn |
| Mar 31, 2023 | 1.83 Mn |
| Dec 31, 2022 | 1.87 Mn |
| Sep 30, 2022 | 338,000.00 |
| Jun 30, 2022 | 73.75 Mn |
| Mar 31, 2022 | 1.69 Mn |
| Dec 31, 2021 | 10.00 Mn |
| Sep 30, 2021 | 2.34 Mn |